Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging
暂无分享,去创建一个
M. Pompili | M. Giuga | A. Gasbarrini | M. Pompili | F. Giuliante | L. Bonomo | L. Riccardi | L. Miele | A. Gaetano | F. Vecchio | L. Bonomo | A. Gatto | A. M. De Gaetano | M. Ciresa | L. Siciliani | L. Miele | L. Riccardi | F. Pizzolante | G. L. Rapaccini | A. Gasbarrini | F. Giuliante | F. M. Vecchio | G. Rapaccini | F. Pizzolante | L. Siciliani | A. Gatto | M. Ciresa | Maurizio Pompili | M. Giuga | Lorenzo Bonomo
[1] M. Roncalli,et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. , 2003, Journal of hepatology.
[2] V. Lorusso,et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.
[3] R. Manfredi,et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd‐BOPTA) , 1999, Journal of magnetic resonance imaging : JMRI.
[4] Jae Young Lee,et al. The Value of Gadobenate Dimeglumine-Enhanced Delayed Phase MR Imaging for Characterization of Hepatocellular Nodules in the Cirrhotic Liver , 2008, Investigative radiology.
[5] K J Rothman,et al. No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.
[6] A. Giovagnoni,et al. Detection of Malignant Primary Hepatic Neoplasms with Gadobenate Dimeglumine (Gd-BOPTA) Enhanced T1-Weighted Hepatocyte Phase MR Imaging: Results of Off-site Blinded Review in a Phase-II Multicenter Trial , 2001, Korean journal of radiology.
[7] Osamu Matsui,et al. Imaging of Multistep Human Hepatocarcinogenesis by CT during Intra-Arterial Contrast Injection , 2004, Intervirology.
[8] O. Matsui,et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. , 1991, Radiology.
[9] Michiie Sakamoto,et al. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.
[10] Y. N. Park,et al. Dysplastic nodules and hepatocarcinogenesis. , 2002, Clinics in liver disease.
[11] S. Hussain,et al. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. , 2002, Radiographics : a review publication of the Radiological Society of North America, Inc.
[12] HCC Diagnosis with Liver-Specific MRI – Close to Histopathology , 2009, Digestive Diseases.
[13] E. Rummeny,et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. , 2000, AJR. American journal of roentgenology.
[14] I. Wanless,et al. Terminology of nodular hepatocellular lesions , 1995 .
[15] L. Jacks,et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. , 2011, Radiology.
[16] C. Bartolozzi,et al. Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR , 2011, Abdominal Imaging.
[17] Young Kon Kim,et al. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions , 2004, European Radiology.
[18] F. Akisik,et al. Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? , 2011, Clinical radiology.
[19] O. Matsui,et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis , 2011, Abdominal Imaging.
[20] A. Spinazzi,et al. Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.
[21] H. Popper. American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .
[22] T. Perneger. What's wrong with Bonferroni adjustments , 1998, BMJ.
[23] B. Jenkins,et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.
[24] J. Willatt,et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.
[25] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[26] N. Faccioli,et al. Solid Hypervascular Liver Lesions: Accurate Identification of True Benign Lesions on Enhanced Dynamic and Hepatobiliary Phase Magnetic Resonance Imaging After Gadobenate Dimeglumine Administration , 2011, Investigative radiology.
[27] Yoshiyuki Suzuki,et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis , 2006, Cancer.
[28] G. Morana,et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application. , 1996, Radiology.
[29] Singal Amit,et al. Screening for hepatocellular carcinoma. , 2008, Gastroenterology & hepatology.
[30] H. Uchino,et al. DEPARTMENT OF INTERNAL MEDICINE , 1966 .